Doubt they would be gutting the trial process to the point where safety is compromised. Plenty of drugs on market with quite nasty side effects because of a risk reward profile acceptable enough for the condition.
Take the RP11 treatment for example, just doing a delta improvement type trial only would need 36 months as it stands - where as a theoretical acceleration might ask for 18 months and give conditional approval, pending full data read out at 36.
DXB I believe has this around eFGR data that an interim point shows improvement for a conditional approval, but still will require the full two years.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)